Bliss GVS Pharma Limited (BLISSGVS) Fair Value & Analysis
Healthcare · IN · Market cap ₹58.0B (≈ $614M) · ISIN INE416D01022
What is Bliss GVS Pharma Limited really worth?
A solid business, but trading 321% above our fair value of ₹158.96.
As of Aug 19, 2026, the fair value of Bliss GVS Pharma Limited is ₹158.96 per share against a price of ₹668.70, so the fair value sits 76% below the price. A model estimate blended from multiple valuation models, recalculated regularly.
Strengths
Risks
Fair value as of: Aug 19, 2026
From 24 valuation models · updated 18 days ago
Share price +32.4% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (₹229.47). The favourable scenario is already priced in.
- Solid but not exceptional quality (66/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (₹100.00 to ₹229.47) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 19, 2026.
How to read this chart
60‑month range ₹65.30 – ₹668.70 · fair‑value band ₹100.00 – ₹229.47 · the ₹668.70 price screens above the ₹158.96 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 19, 2026.
Analysis
Bliss GVS Pharma Limited (BLISSGVS) currently trades at ₹668.70, while our model-based Fair Value estimate is ₹158.96, implying the stock looks roughly 320.7% overvalued today. The Quality Score stands at 66/100 (solid quality), in the Healthcare sector. Bull case: the Growth Earnings group reads highest at a median of ₹228.78 per share, and 0 of the 24 models we run sit above the ₹668.70 price. Bear case: the Earnings-Based group reads lowest at ₹68.53, and 24 of the 24 models stay below the price. Evidence for this calculation is high.
Over the trailing twelve months, Bliss GVS Pharma Limited generated revenue of ₹10.1B at a net margin of 13.6%. Revenue grew 37.6% year over year. It earns a return on equity of 11.6%. Net debt stands at ₹472M. Fundamentals as of Aug 19, 2026
Our scenario range runs from ₹100.00 (bear case) to ₹229.47 (bull case); at ₹668.70, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −76%, BLISSGVS screens richer than that median.
Fair Value models
This estimate rests on fiscal year 2026 figures, and about 5 months have passed since. In that time the company retained roughly ₹5.50 per share, which is 2.6 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 24 models by family
Widest divergence: Growth Earnings (₹228.78) versus Earnings-Based (₹68.53). Highest evidence: FCF DCF (80).
Notify me when BLISSGVS reaches fair value
Put BLISSGVS on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 19, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 65 · Market factors (momentum, volatility) 78
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Bliss GVS Pharma Limited develops, manufactures, and markets pharmaceutical formulations in India and internationally. The company offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear drops, injections, liquid preparations, lozenges, nasal solutions, oral solids, …
Full company description
Bliss GVS Pharma Limited develops, manufactures, and markets pharmaceutical formulations in India and internationally. The company offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear drops, injections, liquid preparations, lozenges, nasal solutions, oral solids, parenterals, pessaries, sachets, soft gelatin capsules, suppositories, suspensions, topical preparations, and transdermal patches. It also provides other healthcare products, such as balms, nasal inhalers, over-the-counter products, petroleum jellies, roll-ons, soaps, sprays, and vaginal washes. In addition, the company offers therapeutic products consisting of analgesics, antacids, anxiolytics, and haematinics; anti-bacterials, antibiotics, anti-diabetics, anti-diarrheals, anti-emetics, antifungals, anti-haemorrhoidals, anti-helmintics, anti-infectives, anti-inflammatories, anti-malarials, anti-microbials, anti-migraines, anti-oxidants, anti-protozoals, anti-pyretics, anti-septics, anti-spasmodics, anti-ulcers, and anti-ulcerants; cough syrups and nasal decongestants; and products for erectile dysfunction, laryngitis, and pharyngitis. Further, it provides and anti-dandruff shampoos, appetizers, hand sanitizers, health and nutritional supplements, insecticides, mosquito repellants, moisturizers, prickly heat powders, skin lightening lotions, vaginal contraceptives, vaginal hygiene products, and vitamin supplements; and amino acid preparations, iron tonics, antitussives, appetite stimulants, anti-allergics, body supplements, ear wax solvents, and oral rehydration products. The company exports its products. Bliss GVS Pharma Limited was incorporated in 1984 and is based in Mumbai, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Bliss GVS Pharma Limited reported revenue of ₹9.2B in FY2026 versus ₹7.4B in FY2022, a compound +5.7%/yr. Reported net income was ₹1.3B in FY2026, compounding +71.2%/yr from FY2022. FY2022 was a trough year, so the rate overstates the trend.
BLISSGVS screens 321% overvalued. Compare with Merck KGaA →
Peer Group
Drug Manufacturers - Specialty & Generic · 609 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Merck KGaA MRK | €140.25 | €106.48 | −24% |
| Takeda Pharmaceutical Company TAK | $18.03 | $11.11 | −38% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | −52% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,899 | ₹989.50 | −48% |
| Galderma Group GALD | CHF 178.55 | CHF 55.07 | −69% |
| Haleon plc HLN | $10.11 | $7.64 | −24% |
| Teva Pharmaceutical Industries Limited TEVA | $36.05 | $15.33 | −57% |
| Sandoz Group SDZ | CHF 70.66 | CHF 39.21 | −45% |
| Zoetis Inc ZTS | $77.10 | $104.88 | +36% |
| Hansoh Pharmaceutical Group 3692 | HK$35.12 | HK$16.18 | −54% |
Compare Bliss GVS Pharma Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Bliss GVS Pharma Limited (BLISSGVS) overvalued or undervalued?
What is the fair value of BLISSGVS?
What is the quality score of BLISSGVS?
What is the price target for Bliss GVS Pharma Limited (BLISSGVS)?
What is the Bliss GVS Pharma Limited stock forecast for 2026?
What is the revenue of Bliss GVS Pharma Limited (BLISSGVS)?
What is the net profit margin of BLISSGVS?
Does Bliss GVS Pharma Limited pay a dividend?
Watch Bliss GVS Pharma Limited in the live analysis
One click puts Bliss GVS Pharma Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.